Terms: = Kidney tumors AND CgA AND Treatment
11 results:
1. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
2. [Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis].
Shen Q; Liu YX; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):276-282. PubMed ID: 37042138
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.
Pierantoni F; Basso U; Maruzzo M; Lamberti E; Bimbatti D; Tierno G; Bergo E; Brunello A; Zagonel V
J Geriatr Oncol; 2021 Mar; 12(2):290-297. PubMed ID: 32972885
[TBL] [Abstract] [Full Text] [Related]
4. Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center.
Zhai H; Ma X; Nie W; Li H; Peng C; Li X; Zhang Y; Zhang X
Clin Genitourin Cancer; 2017 Oct; 15(5):e765-e771. PubMed ID: 28688872
[TBL] [Abstract] [Full Text] [Related]
5. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.
Ito T; Hijioka S; Masui T; Kasajima A; Nakamoto Y; Kobayashi N; Komoto I; Hijioka M; Lee L; Igarashi H; Jensen RT; Imamura M
J Gastroenterol; 2017 Jan; 52(1):9-18. PubMed ID: 27539256
[TBL] [Abstract] [Full Text] [Related]
6. Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.
Brunello A; Basso U; Sacco C; Sava T; De Vivo R; Camerini A; Barile C; Roma A; Maruzzo M; Falci C; Zagonel V
Ann Oncol; 2013 Feb; 24(2):336-342. PubMed ID: 23051952
[TBL] [Abstract] [Full Text] [Related]
7. Systemic therapies for metastatic renal cell carcinoma in older adults.
Pal SK; Vanderwalde A; Hurria A; Figlin RA
Drugs Aging; 2011 Aug; 28(8):635-49. PubMed ID: 21812499
[TBL] [Abstract] [Full Text] [Related]
8. Chromogranin A (cga)--the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood.
Glinicki P; Jeske W
Endokrynol Pol; 2010; 61(4):384-7. PubMed ID: 20806183
[TBL] [Abstract] [Full Text] [Related]
9. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.
Swärd C; Bernhardt P; Ahlman H; Wängberg B; Forssell-Aronsson E; Larsson M; Svensson J; Rossi-Norrlund R; Kölby L
World J Surg; 2010 Jun; 34(6):1368-72. PubMed ID: 20066413
[TBL] [Abstract] [Full Text] [Related]
10. Cancer chemotherapy in the older cancer patient.
Carreca I; Balducci L
Urol Oncol; 2009; 27(6):633-42. PubMed ID: 19879474
[TBL] [Abstract] [Full Text] [Related]
11. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
Leja J; Dzojic H; Gustafson E; Oberg K; Giandomenico V; Essand M
Clin Cancer Res; 2007 Apr; 13(8):2455-62. PubMed ID: 17438105
[TBL] [Abstract] [Full Text] [Related]
